Elpiscience Biopharmaceuticals presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting. Check out the highlights.
Elpiscience Biopharmaceuticals today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.
Elpiscience Biopharmaceuticals announced that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.
Join us at BIO-Europe Spring 2023.
Elpiscience Biopharmaceutical today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).
Elpiscience today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P.Morgan